NCT03909269View on ClinicalTrials.gov

Glycaemic Markers in Persons With Type 2 Diabetes on Haemodialysis

CompletedOBSERVATIONAL
Enrollment

88

Participants

Timeline

Start Date

April 1, 2018

Primary Completion Date

April 1, 2020

Study Completion Date

April 1, 2020

Conditions
Diabetic Nephropathy Type 2Type2 Diabetes
Interventions
DEVICE

Continuous glucose monitoring

Continuous glucose monitoring five times over 17 weeks

DIAGNOSTIC_TEST

Glycaemic markers

Measurement of HbA1c by immunoassay (Roche) and chromatography (TOSOH), including glycated albumin and fructosamine.

RADIATION

Erythrocyte life span

Erythrocyte life span measured by Crom-51 labelling over 4 weeks

DEVICE

Carbon monoxide (CO)-rebreathing method

Measurement of total blood volume, plasma volume and erythrocyte volume

Trial Locations (1)

2100

Rigshospitalet, København Ø

All Listed Sponsors
collaborator

Steno Diabetes Center Copenhagen

OTHER

lead

Rigshospitalet, Denmark

OTHER

NCT03909269 - Glycaemic Markers in Persons With Type 2 Diabetes on Haemodialysis | Biotech Hunter | Biotech Hunter